1. Home
  2. Boehringer

Tags : Boehringer

Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program
M&A

Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for

Tuba Khan December 10, 2020

Shots: The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development […]Read More

PharmaShots Weekly Snapshot (Oct 12-16, 2020)
Weekly Snapshot

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Tuba Khan October 16, 2020

Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, Luxturna, Novartis, receives, voretigene neparvovec Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis Published: Oct 15, […]Read More

Boehringer Ingelheim’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for Systemic Sclerosis Associated ILD
Regulatory

Boehringer Ingelheim’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for

Tuba Khan July 26, 2019

Shots: The FDA’s Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) The FDA’s recommendation is based on P-III SENSCIS study assessing Ofev vs PBO in 576 patients SSc-ILD resulted in a reduction in loss of pulmonary function by 44% and @52wks. rate of decline […]Read More

NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab for the treatment of r/r cHL
Pharma

NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab

Vartika Singh September 4, 2018

Shots:  Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method, supply of GMP clinical material, and CMC filing support with the NMPA Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting